Indication
Endocrine Tumors
2 clinical trials
4 products
3 drugs
Clinical trial
Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine TumourStatus: Completed, Estimated PCD: 2013-04-01
Product
PlaceboProduct
LanreotideClinical trial
A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients With Metastatic CancerStatus: Recruiting, Estimated PCD: 2027-03-23
Drug
cyclophosphamideDrug
fludarabineDrug
IL-2Product
Pembrolizumab